We couldn’t find a better way to start off 2021 at Enantis. We are happy to announce our successful grant application for TACR TREND „Technology Leaders“ programme! To our great delight, the project was ranked the second one in life science category and 14th all together from the 434 applications.

Our project will focus on development and commercialization of new stable FGF molecules from our research pipeline that are planned to be used as reagents in stem cell research. High intrinsic instability of these molecules prevents their widespread use and thanks to our collaboration with Masaryk University, we will be able to apply advanced AI-based protein engineering approaches to stabilize these innovative molecules and bring their high added value to the customers.

This grant will help Enantis broaden the product portfolio and focus on the internal R&D even in these times of uncertainty. Big thanks to the Technology Agency of the Czech Republic #TACR and everyone who contributed to this effort!

#biotech #brnoregion #proteinengineering

Meet Enantis: Part 7

Over the next few months, this series will introduce the people behind Enantis.

The seventh part of our series is about Kateřina Kailová, Advanced Laboratory Technician at Enantis.

Read more in the picture!

We are excited to announce that the European Patent covering the hyper stable form of FGF2 has just been granted to Enantis and Masaryk University. We have worked really hard to get here. The next step is granting of the US patent to have a full IP protection and we hope this happens soon as well.

Over the next few months, this series will introduce the people behind Enantis.

The sixth part of our series is about Eliška Petulová, Advanced Laboratory Technician at Enantis.

Read more in the picture!

Enantis is honoured to be listed in this year’s European Biotechnology Science & Industry Guide as the only company from the Czech Republic. The 10th edition of the Guide is showcasing brilliant science and excellent business from companies, universities, research institutes, and expert support providers.

Our profile describes what we can do and what services we are able to provide to our customers.

You can either collect a copy from us, obtain the guide at selected conferences or order one from Amazon.

As a response to the recent coronavirus outbreak, Enantis joined the international efforts and became a member of FASTCURE consortium (https://fastcure.net/).
The goal of this initiative is to employ structural targeting of coronavirus using repurposing and efficient diagnostics. Enantis will contribute with computational analysis of protein-ligand complexes, compound transport process analysis, prediction of disease-related mutations and identification of mutagenesis hotspots.
The lessons learned, the data management system and automated workflows, from the genome to the drug candidates, will be made available as a cloud-based, distributed, global emergency response system to ensure an immediate and well-coordinated response not only to COVID-19, but also to future outbreaks.

Over the next few months, this series will introduce the people behind Enantis.

The fifth part of our series is about Pavel Brazda, Ph.D., Molecular Biologist and Biochemist.

Read more in the picture!

“The whole start-up scene is progressing dramatically in the last couple of years, especially here in #brnoregion thanks to the JIC support. But this doesn’t apply to biotech, unfortunately. Since the biotech ecosystem is underdeveloped, outsiders may not be confident in the prospects of Czech companies in this field. The only way to persuade them otherwise is with our products and expertise. And we work hard to break this glass ceiling.“ says Roman Badik, CEO of Enantis, in the interview for PharmaBoardroom.

Read it here: https://lnkd.in/exahw4b